AstraZeneca Pharma India Ltd. (NSE:ASTRAZEN) is a leading biopharmaceutical company that operates in India. The company manufactures and markets prescription drugs for a wide range of therapeutic areas, including cardiovascular, respiratory, neuroscience, and oncology. They also offer a range of innovative and specialty medicines, including biologics and biosimilars. With a strong focus on research and development, AstraZeneca Pharma India Ltd. is committed to improving patient outcomes and addressing unmet medical needs. The company is a subsidiary of AstraZeneca, a global pharmaceutical company headquartered in the United Kingdom.<\/p>\n\n\n\n
AstraZeneca Pharma India Ltd. reported a total income of Rs. 257.0046 crores for the period ended December 31, 2022, compared to Rs. 242.9211 crores for the period ended September 30, 2022. The company’s net profit for the same period was Rs. 29.3044 crores, a decrease from the net profit of Rs. 32.5643 crores reported for the previous period. However, the company’s total income for the period ended December 31, 2022, showed an increase from the same period in the previous year, with Rs. 257.0046 crores reported compared to Rs. 205.8678 crores in 2021. Similarly, the net profit for the same period also increased, with Rs. 29.3044 crores reported compared to Rs. 11.4192 crores in 2021. In terms of earnings per share (EPS), AstraZeneca Pharma India Ltd. reported an EPS of Rs. 11.72 for the period ended December 31, 2022, compared to Rs. 13.03 for the period ended September 30, 2022. The EPS for the same period in the previous year was Rs. 4.57.<\/p>\n\n\n\n
For the 9 Months period ended December 31, 2022, the company reported a total income of Rs. 738.3719 crores, an increase from Rs. 584.7105 crores reported during the same period in the previous year. The company’s net profit for the 9 Months period ended December 31, 2022, was Rs. 82.0213 crores, an increase from Rs. 33.8096 crores reported during the same period in the previous year. The EPS for the 9 Months period ended December 31, 2022, was Rs. 32.81, an increase from Rs. 13.44 reported during the same period in the previous year.<\/p>\n\n\n\n
Overall, while the company’s net profit for the period ended December 31, 2022, decreased compared to the previous period, it showed an increase compared to the same period in the previous year. The company’s total income and EPS also showed an increase for the same period.<\/p>\n","protected":false},"excerpt":{"rendered":"
AstraZeneca Pharma India Ltd. (NSE:ASTRAZEN) is a leading biopharmaceutical company that operates in India. The company manufactures and markets prescription drugs for a wide range of therapeutic areas, including cardiovascular, respiratory, neuroscience, and oncology. They also offer a range of innovative and specialty medicines, including biologics and biosimilars. With a strong focus on research and […]<\/p>\n","protected":false},"author":1932,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[392,5747],"tags":[1115],"class_list":["post-142548","post","type-post","status-publish","format-standard","hentry","category-earnings","category-healthcare-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":168730,"url":"https:\/\/alphastreet.com\/india\/astrazeneca-pharma-india-ltd-q4fy25-3-rise-in-revenue\/","url_meta":{"origin":142548,"position":0},"title":"Astrazeneca Pharma India Ltd Q4FY25; 3% rise in Revenue","author":"Divyansh_Kasana","date":"June 10, 2025","format":false,"excerpt":"AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products. Financial Results: Astrazeneca Pharma India Ltd reported Revenues for Q4FY25 of \u20b91,000.00 Crores up from \u20b9974.00 Crore year on year, a rise of 2.67%. Total Expenses for Q4FY25 of \u20b9914.00 Crores up from\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-6.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-6.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-6.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-6.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-6.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-6.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":167105,"url":"https:\/\/alphastreet.com\/india\/astrazeneca-pharma-india-ltd-q3fy25-69-fall-in-profits\/","url_meta":{"origin":142548,"position":1},"title":"Astrazeneca Pharma India Ltd Q3FY25; 69% fall in Profits","author":"Divyansh_Kasana","date":"February 27, 2025","format":false,"excerpt":"AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products. Financial Results: Astrazeneca Pharma India Ltd reported Revenues for Q3FY25 of \u20b91,050.00 Crores up from \u20b9955.00 Crore year on year, a rise of 9.95%. Total Expenses for Q3FY25 of \u20b9957.00 Crores up from\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/T.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/T.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/T.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/T.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/T.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/T.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":154136,"url":"https:\/\/alphastreet.com\/india\/astrazeneca-pharma-india-ltd-q1fy24-170-rise-in-profits\/","url_meta":{"origin":142548,"position":2},"title":"Astrazeneca Pharma India Ltd Q1FY24; 170% rise in Profits","author":"Divyansh_Kasana","date":"August 16, 2023","format":false,"excerpt":"AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products. Financial Results: Astrazeneca Pharma India Ltd reported Revenues for Q1FY24 of \u20b9295.00 Crores up from \u20b9232.00 Crore year on year, a rise of 27.16%. Total Expenses for Q1FY24 of \u20b9232.00 Crores up from\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-1144.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-1144.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-1144.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-1144.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-1144.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-1144.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":157083,"url":"https:\/\/alphastreet.com\/india\/astrazeneca-pharma-india-ltd-q2fy24-58-rise-in-profits\/","url_meta":{"origin":142548,"position":3},"title":"Astrazeneca Pharma India Ltd Q2FY24; 58% rise in Profits","author":"Divyansh_Kasana","date":"December 4, 2023","format":false,"excerpt":"AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products. Financial Results: Astrazeneca Pharma India Ltd reported Revenues for Q2FY24 of \u20b9311.00 Crores up from \u20b9236.00 Crore year on year, a rise of 31.78%. Total Expenses for Q2FY24 of \u20b9262.00 Crores up from\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-27.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-27.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-27.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-27.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-27.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/12\/image-27.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170207,"url":"https:\/\/alphastreet.com\/india\/astrazeneca-pharma-q1-fy26-earnings-results\/","url_meta":{"origin":142548,"position":4},"title":"Astrazeneca Pharma Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 15, 2025","format":false,"excerpt":"AstraZeneca Pharma India Limited is engaged in the manufacture, distribution, and marketing of pharmaceutical products. Below are its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b9826 crore, up 29.06% year-on-year (YoY) from \u20b9640 crore in Q1 FY25. Total Expenses: \u20b9726 crore, up 20.40% YoY from \u20b9603 crore. Consolidated\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"ASTRAZEN Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":165856,"url":"https:\/\/alphastreet.com\/india\/asian-paints-ltd-q2fy25-44-fall-in-profits-3\/","url_meta":{"origin":142548,"position":5},"title":"Asian Paints Ltd Q2FY25; 44% fall in Profits","author":"Divyansh_Kasana","date":"December 2, 2024","format":false,"excerpt":"AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products. Financial Results: Astrazeneca Pharma India Ltd reported Revenues for Q2FY25 of \u20b98,028.00 Crores down from \u20b98,479.00 Crore year on year, a fall of 5.32%. Total Expenses for Q2FY25 of \u20b97,093.00 Crores up from\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/HJ.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/HJ.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/HJ.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/HJ.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/HJ.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/HJ.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/142548","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=142548"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/142548\/revisions"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=142548"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=142548"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=142548"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}